Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Rothrock

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Headache|June 30, 2005
Predictors of a negative response to topiramate therapy in patients with chronic migraineJohn F Rothrock, Victoria A Parada, Renay Drinkard, et al.
Headache|October 10, 2014
Real-world economic impact of onabotulinumtoxinA in patients with chronic migraineJohn F Rothrock, Lisa M Bloudek, Timothy T Houle, et al.
Headache|May 27, 2024
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraineRima M Dafer, Gretchen E Tietjen, John F Rothrock, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
Mayo Clinic Proceedings|October 14, 2006
Assessing the ability of topiramate to improve the daily activities of patients with migraineJan Lewis Brandes, David B Kudrow, John F Rothrock, et al.
Headache|September 28, 2019
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineJohn F Rothrock, Aubrey Manack Adams, Richard B Lipton, et al.
The Journal of Headache and Pain|February 3, 2019
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL StudyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
The Journal of Headache and Pain|January 24, 2019
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL studyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
Current Medical Research and Opinion|September 28, 2011
Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidenceJohn F Rothrock, Roger K Cady, Sheena K Aurora, et al.
Headache|August 5, 2011
Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptansRoger K Cady, Sheena K Aurora, Jan L Brandes, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Headache|June 30, 2005
Predictors of a negative response to topiramate therapy in patients with chronic migraineJohn F Rothrock, Victoria A Parada, Renay Drinkard, et al.
Headache|October 10, 2014
Real-world economic impact of onabotulinumtoxinA in patients with chronic migraineJohn F Rothrock, Lisa M Bloudek, Timothy T Houle, et al.
Headache|May 27, 2024
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraineRima M Dafer, Gretchen E Tietjen, John F Rothrock, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
Mayo Clinic Proceedings|October 14, 2006
Assessing the ability of topiramate to improve the daily activities of patients with migraineJan Lewis Brandes, David B Kudrow, John F Rothrock, et al.
Headache|September 28, 2019
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineJohn F Rothrock, Aubrey Manack Adams, Richard B Lipton, et al.
The Journal of Headache and Pain|February 3, 2019
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL StudyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
The Journal of Headache and Pain|January 24, 2019
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL studyWilliam B Young, J Ivan Lopez, John F Rothrock, et al.
Current Medical Research and Opinion|September 28, 2011
Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidenceJohn F Rothrock, Roger K Cady, Sheena K Aurora, et al.
Headache|August 5, 2011
Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptansRoger K Cady, Sheena K Aurora, Jan L Brandes, et al.
Pageof 10